Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.9
2.7
Journals
Animals
Special Issues
Advancement in Small Animals Oncology
share announcement

Advancement in Small Animals Oncology

A special issue of Animals (ISSN 2076-2615). This special issue belongs to the section "Veterinary Clinical Studies".

Deadline for manuscript submissions: closed (1 May 2023) | Viewed by 7958

Special Issue Editor

Dr. Antonio Giuliano

E-Mail Website
Guest Editor
Department of Veterinary Clinical Sciences, Jockey Club College of Veterinary Medicine, City University of Hong Kong, Kowloon, Hong Kong
Interests: improve the quality of life of pets with cancers; tyrosine kinase inhibitors; immunotherapy; radiotherapy; electrochemotherapy; clinical investigations of new anti-neoplastic drugs/treatments; development of rapid tests for TCC diagnosis and prognosis

Special Issue Information

Dear Colleagues,

Cancer is one of the leading causes of death among people as well as among dogs and cats. In the last few years, small animal oncology has rapidly progressed . Molecular tests for specific cancers detection, liquid biopsies, and comprehensive genomic fingerprint analyses of cancer specimens are now a reality for dogs as well as people. Implementation of sophisticated diagnostic techniques such as liquid biopsy holds promise for the early diagnosis and better prognosis of various cancer types. The use of genomic fingerprint analysis in pets makes way for personalized medicine with individualized tailored treatments based on specific genetic mutations.

However, despite the recent general advances in small animal oncology, the number of anticancer drugs available for pets, especially tyrosine kinase inhibitors and immunotherapies, is insignificant compared with the array of treatment options available for people. Prognosis and treatment strategies for many tumors in dogs and cats have not changed much in the last 20 years. More research is required to understand the exact molecular biologies and pathologies of different types of neoplasia and to improve the treatment and quality of life for dogs and cats with cancer.

We are pleased to invite you to submit original research papers, reviews, case series, and cases reports regarding advances in small animal cancer diagnosis, prognosis, and treatment, as well as studies and reviews focusing on comparative and translational oncology.

We look forward to receiving your contributions.

Dr. Antonio Giuliano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Animals is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • small animal oncology
  • cat
  • dog
  • oncology
  • cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

8 pages, 243 KiB  
Article
Retrospective Study of T Cell Leukaemia (Large Granular Lymphocyte Variant) in Dogs Associated with Suspected Immune-Mediated Cytopaenia(s) in the Absence of Peripheral Lymphocytosis
by Angelo Capasso, Elizabeth Villers, James Elliott, Nic Ilchyshyn, Ian Hopkins, Ferran Valls Sanchez and Sara Verganti
Animals 2023, 13(3), 357; https://doi.org/10.3390/ani13030357 - 20 Jan 2023
Viewed by 2986
Abstract
Canine chronic large granular lymphocyte (LGL) leukaemia is commonly characterised by moderate to marked lymphocytosis but not neutropaenia. In humans, LGL leukaemia is often associated with autoimmune disorders, including immune-mediated cytopaenias (mainly neutropaenia). This presentation is rare in dogs. The aim of this [...] Read more.
Canine chronic large granular lymphocyte (LGL) leukaemia is commonly characterised by moderate to marked lymphocytosis but not neutropaenia. In humans, LGL leukaemia is often associated with autoimmune disorders, including immune-mediated cytopaenias (mainly neutropaenia). This presentation is rare in dogs. The aim of this retrospective study was to describe the clinical characteristics, treatments, and outcomes of dogs with chronic LGL leukaemia with suspected immune-mediated cytopaenia. Six dogs with a median age of 4.5 years (range 2–8 years) were included in the study. The most common presenting signs were pyrexia and lethargy. All dogs had severe neutropaenia (median neutrophil count 0.07 × 109/L), three had thrombocytopaenia (median platelet count 66 × 109/L), and one had anaemia (HCT 0.32 L/L). In all dogs, bone marrow cytology revealed infiltration of granular T lymphocytes; PARR analysis confirmed clonality in four, and bone marrow flow cytometry identified CD3+ CD8+ neoplastic cells in two cases. All patients received systemic chemotherapy, and the cytopaenias resolved after 1–19 weeks. Two dogs were euthanised 133 and 322 days after diagnosis, two were lost to follow-up after 224 and 357 days, and two were alive at 546 and 721 days. A subset of LGL leukaemia in dogs is associated with immune-mediated cytopaenia and has a unique clinical presentation. Full article
(This article belongs to the Special Issue Advancement in Small Animals Oncology)

Review

Jump to: Research

22 pages, 1203 KiB  
Review
Repurposing Drugs in Small Animal Oncology
by Antonio Giuliano, Rodrigo S. Horta, Rafael A. M. Vieira, Kelly R. Hume and Jane Dobson
Animals 2023, 13(1), 139; https://doi.org/10.3390/ani13010139 - 29 Dec 2022
Cited by 4 | Viewed by 4510
Abstract
Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, [...] Read more.
Repurposing drugs in oncology consists of using off-label drugs that are licensed for various non-oncological medical conditions to treat cancer. Repurposing drugs has the advantage of using drugs that are already commercialized, with known mechanisms of action, proven safety profiles, and known toxicology, pharmacokinetics and pharmacodynamics, and posology. These drugs are usually cheaper than new anti-cancer drugs and thus more affordable, even in low-income countries. The interest in repurposed anti-cancer drugs has led to numerous in vivo and in vitro studies, with some promising results. Some randomized clinical trials have also been performed in humans, with certain drugs showing some degree of clinical efficacy, but the true clinical benefit for most of these drugs remains unknown. Repurposing drugs in veterinary oncology is a very new concept and only a few studies have been published so far. In this review, we summarize both the benefits and challenges of using repurposed anti-cancer drugs; we report and discuss the most relevant studies that have been previously published in small animal oncology, and we suggest potential drugs that could be clinically investigated for anti-cancer treatment in dogs and cats. Full article
(This article belongs to the Special Issue Advancement in Small Animals Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop